SOUTH SAN FRANCISCO,
California, June 2, 2017
/PRNewswire/ -- ShangPharma Innovation (SPI) announced the
appointment of Peter DiLaura, Ravi
Kiron MBA PhD, Krishna Kodukula PhD, and Robert Wild PhD to its
founding Executive-In-Residence (EIR) team.
The EIR team will provide ShangPharma Innovation with expert
advice on business, scientific, and strategic development of
biomedical initiatives, including the identification and assessment
of novel opportunities for early-stage equity investments and new
venture incubator tenants at SPI's South
San Francisco facility. They will also participate in the
negotiation and management of collaborations, licenses, and
partnerships.
Mr. DiLaura is a life sciences executive based in San Francisco, CA. He currently advises a
number of biotechnology and pharmaceutical companies and investors,
and was CEO of Second Genome, a pioneering microbiome therapeutics
company, from seed financing through clinical development.
Previously, Mr. DiLaura held a range of executive roles in the
systems biology company Ingenuity Systems (Qiagen), with
responsibility for commercial operations, sales and marketing,
product strategy, and corporate development. He was also a
Consultant at The Wilkerson Group, providing strategic consulting
to biotech, pharma, medical device, and diagnostic companies and
investors. He holds a BS in Economics from The Wharton School at
the University of Pennsylvania.
Dr. Kiron, based in San Jose,
CA, is an experienced pharma/biotech executive with decades
of experience from early drug discovery through late-stage clinical
development, intellectual property, regulatory strategy and product
commercialization. Dr. Kiron has consulted for dozens of life
sciences companies, founded and led multiple new ventures, was an
EIR at SRI Ventures, and serves currently on many company and
non-profit boards. Dr. Kiron has also held operational &
executive roles at Pfizer and J&J/Alza in cardiovascular and
oncology R&D and strategic business development. He has a wide
breadth of hands-on experience negotiating and executing
partnerships, mergers and acquisitions (WLA, PHA, biotechs), and
has extensive global networks. Previously, he was a faculty member
at Cornell University Medical College
and at University of Rhode Island. Dr.
Kiron earned BS and MS degrees from the University of Mumbai, a PhD from the Indian Institute of
Science, and an MBA from Rensselaer
Polytechnic Institute.
Dr. Kodukula, based in Princeton,
NJ, is a pharmaceutical professional with decades of
experience in the industry and non-profit sectors, in research and
business roles. Previously, he was Executive Director, Strategic
Development at SRI Biosciences (Stanford Research Institute); Site
Head and Founder of SRI Shenandoah Valley; Distinguished Member of
Technical Staff at Sarnoff Corporation; in leadership/founder roles
at Pyxis Technology Solutions and Small Molecule Therapeutics; and
in research scientist positions at Bristol-Myers Squibb and
Hoffmann-LaRoche. Dr. Kodukula has served on many boards, including
several gubernatorial appointments, and has been listed as one of
50 most influential business leaders in Virginia. Dr. Kodukula received undergraduate
and graduate degrees at Andhra and Utkal Universities in
India, and did postdoctoral work
at the Indian Institute of Science and Roche Institute of Molecular
Biology.
Dr. Wild, based in San Diego,
CA, is a seasoned R&D executive with almost 20 years of
broad biotech/pharma industry experience in drug discovery and
development, spanning both small molecules and biologics. He
currently advises a number of biotechnology and pharmaceutical
companies and investors. Dr. Wild has contributed to the
advancement of numerous clinical development candidates, including
four FDA-approved oncology therapeutics. Dr. Wild previously served
as CSO and Senior VP Research at Ignyta; CSO Oncology Research at
Eli Lilly; Senior Director at OSI (Astellas); and as a research
scientist at Bristol-Myers Squibb and Sugen. He received his
undergraduate and graduate degrees at the University of
Minnesota.
Dr. Walter H. Moos, CEO of
ShangPharma Innovation, commented, " Our EIR colleagues greatly
strengthen our global leadership capabilities. With their
successful entrepreneurial, biotech and pharma experience, and
global executive-level relationships, they will help us expand and
manage our innovation practice in all phases of biomedical R&D.
We anticipate naming additional leaders to our team in the near
future."
ShangPharma Innovation facilitates and accelerates drug
discovery, focusing on both therapeutics and technology platforms,
and offers funding, incubator space, and other support to its
collaborators, partners, and tenants. This includes sponsoring
proof-of-concept research at academic and major medical centers,
research institutes, and seed-stage start-ups, leading to industry
collaborations and venture capital financing.
---
FOR MORE
INFORMATION
ShangPharma Innovation, Inc.
www.ShangPharmaInnovation.com
info@shangpharmainnovation.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shangpharma-innovation-names-founding-executive-in-residence-team-300467573.html
SOURCE ShangPharma Corporation